Concert Pharmaceuticals Announces Proposed Public Offering of Common Stock
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/18/2026
- Tech selloff pulls Wall Street to two-week lows as bond yields climb
- Baidu slips as Q2 results miss estimates despite growth in AI cloud business
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Home Depot beats estimates, reaffirms fiscal 2026 guidance
- Citi says positioning risk is shifting from short squeezes to profit-taking
- Wall Street indexes slip as oil prices rise, retail results awaited
- Micron rises as White House presses Apple to avoid Chinese memory chips
- BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
- Tech selloff pulls Wall Street to two-week lows as bond yields climb
- Francisco Partners to acquire Weave Communications for $650M
Concert Pharma (CNCE) Prices 3.3M Common Stock Offering at $15.15/Share
March 19, 2015 9:24 AM EDTConcert Pharma (NASDAQ: CNCE) announced the pricing of an underwritten public offering of 3,300,000 shares of its common stock at a public offering price of $15.15 per share.
All shares in the offering are being sold by Concert, with expected net proceeds to Concert of approximately $46.7... More
Concert Pharma (CNCE) Plans Common Stock Offering
March 18, 2015 4:28 PM EDTConcert Pharma (NASDAQ: CNCE) announced that it has commenced an underwritten public offering of its common stock. All of the shares in the offering are to be sold by Concert.
Wells Fargo and JMP Securities are acting as joint book-running managers for the... More
